The global medical aesthetic treatments market demand is accelerating due to greater affordability, improved treatment outcomes, and increased social acceptance.The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Medical Aesthetic Treatments Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Medical Aesthetic Treatments Market, by Treatment Type
8.1.1. Injectable Aesthetic Treatments
8.1.1.1. Market Revenue and Forecast
8.1.2. Energy-Based Aesthetic Treatments
8.1.2.1. Market Revenue and Forecast
8.1.3. Body Contouring & Cellulite Reduction
8.1.3.1. Market Revenue and Forecast
8.1.4. Facial Aesthetic Treatments
8.1.4.1. Market Revenue and Forecast
8.1.5. Facial Aesthetic Treatments
8.1.5.1. Market Revenue and Forecast
8.1.6. Hair Restoration Treatments
8.1.6.1. Market Revenue and Forecast
8.1.7. Dental Aesthetic Procedures
8.1.7.1. Market Revenue and Forecast
8.1.8. Others
8.1.8.1. Market Revenue and Forecast
9.1. Medical Aesthetic Treatments Market, by Gender
9.1.1. Female
9.1.1.1. Market Revenue and Forecast
9.1.2. Male
9.1.2.1. Market Revenue and Forecast
9.1.3. Others / Non-binary
9.1.3.1. Market Revenue and Forecast
10.1. Medical Aesthetic Treatments Market, by Age Group
10.1.1. 18–25 Years
10.1.1.1. Market Revenue and Forecast
10.1.2. 26–35 Years
10.1.2.1. Market Revenue and Forecast
10.1.3. 36–50 Years
10.1.3.1. Market Revenue and Forecast
10.1.4. 51+ Years
10.1.4.1. Market Revenue and Forecast
11.1. Medical Aesthetic Treatments Market, by Provider Type
11.1.1. Dermatology Clinics
11.1.1.1. Market Revenue and Forecast
11.1.2. MedSpas / Aesthetic Clinics
11.1.2.1. Market Revenue and Forecast
11.1.3. Hospitals & Specialty Clinics
11.1.3.1. Market Revenue and Forecast
11.1.4. Cosmetic Surgery Centers
11.1.4.1. Market Revenue and Forecast
11.1.5. Dental Clinics
11.1.5.1. Market Revenue and Forecast
11.1.6. Others (Home-use Aesthetic Devices by Professionals)
11.1.6.1. Market Revenue and Forecast
12.1. Medical Aesthetic Treatments Market, by End Use Purpose
12.1.1. Anti-aging & Rejuvenation
12.1.1.1. Market Revenue and Forecast
12.1.2. Skin Correction (Acne, Scars, Pigmentation)
12.1.2.1. Market Revenue and Forecast
12.1.3. Body Enhancement / Fat Reduction
12.1.3.1. Market Revenue and Forecast
12.1.4. Hair & Scalp Restoration
12.1.4.1. Market Revenue and Forecast
12.1.5. Cosmetic Dentistry
12.1.5.1. Market Revenue and Forecast
12.1.6. Others
12.1.6.1. Market Revenue and Forecast
13.1. North America
13.1.1. Market Revenue and Forecast, by Treatment Type
13.1.2. Market Revenue and Forecast, by Gender
13.1.3. Market Revenue and Forecast, by Age Group
13.1.4. Market Revenue and Forecast, by Provider Type
13.1.5. Market Revenue and Forecast, by End Use Purpose
13.1.6. U.S.
13.1.6.1. Market Revenue and Forecast, by Treatment Type
13.1.6.2. Market Revenue and Forecast, by Gender
13.1.6.3. Market Revenue and Forecast, by Age Group
13.1.6.4. Market Revenue and Forecast, by Provider Type
13.1.6.5. Market Revenue and Forecast, by End Use Purpose
13.1.7. Rest of North America
13.1.7.1. Market Revenue and Forecast, by Treatment Type
13.1.7.2. Market Revenue and Forecast, by Gender
13.1.7.3. Market Revenue and Forecast, by Age Group
13.1.7.4. Market Revenue and Forecast, by Provider Type
13.1.7.5. Market Revenue and Forecast, by End Use Purpose
13.2. Europe
13.2.1. Market Revenue and Forecast, by Treatment Type
13.2.2. Market Revenue and Forecast, by Gender
13.2.3. Market Revenue and Forecast, by Age Group
13.2.4. Market Revenue and Forecast, by Provider Type
13.2.5. Market Revenue and Forecast, by End Use Purpose
13.2.6. UK
13.2.6.1. Market Revenue and Forecast, by Treatment Type
13.2.6.2. Market Revenue and Forecast, by Gender
13.2.6.3. Market Revenue and Forecast, by Age Group
13.2.7. Market Revenue and Forecast, by Provider Type
13.2.8. Market Revenue and Forecast, by End Use Purpose
13.2.9. Germany
13.2.9.1. Market Revenue and Forecast, by Treatment Type
13.2.9.2. Market Revenue and Forecast, by Gender
13.2.9.3. Market Revenue and Forecast, by Age Group
13.2.10. Market Revenue and Forecast, by Provider Type
13.2.11. Market Revenue and Forecast, by End Use Purpose
13.2.12. France
13.2.12.1. Market Revenue and Forecast, by Treatment Type
13.2.12.2. Market Revenue and Forecast, by Gender
13.2.12.3. Market Revenue and Forecast, by Age Group
13.2.12.4. Market Revenue and Forecast, by Provider Type
13.2.13. Market Revenue and Forecast, by End Use Purpose
13.2.14. Rest of Europe
13.2.14.1. Market Revenue and Forecast, by Treatment Type
13.2.14.2. Market Revenue and Forecast, by Gender
13.2.14.3. Market Revenue and Forecast, by Age Group
13.2.14.4. Market Revenue and Forecast, by Provider Type
13.2.15. Market Revenue and Forecast, by End Use Purpose
13.3. APAC
13.3.1. Market Revenue and Forecast, by Treatment Type
13.3.2. Market Revenue and Forecast, by Gender
13.3.3. Market Revenue and Forecast, by Age Group
13.3.4. Market Revenue and Forecast, by Provider Type
13.3.5. Market Revenue and Forecast, by End Use Purpose
13.3.6. India
13.3.6.1. Market Revenue and Forecast, by Treatment Type
13.3.6.2. Market Revenue and Forecast, by Gender
13.3.6.3. Market Revenue and Forecast, by Age Group
13.3.6.4. Market Revenue and Forecast, by Provider Type
13.3.7. Market Revenue and Forecast, by End Use Purpose
13.3.8. China
13.3.8.1. Market Revenue and Forecast, by Treatment Type
13.3.8.2. Market Revenue and Forecast, by Gender
13.3.8.3. Market Revenue and Forecast, by Age Group
13.3.8.4. Market Revenue and Forecast, by Provider Type
13.3.9. Market Revenue and Forecast, by End Use Purpose
13.3.10. Japan
13.3.10.1. Market Revenue and Forecast, by Treatment Type
13.3.10.2. Market Revenue and Forecast, by Gender
13.3.10.3. Market Revenue and Forecast, by Age Group
13.3.10.4. Market Revenue and Forecast, by Provider Type
13.3.10.5. Market Revenue and Forecast, by End Use Purpose
13.3.11. Rest of APAC
13.3.11.1. Market Revenue and Forecast, by Treatment Type
13.3.11.2. Market Revenue and Forecast, by Gender
13.3.11.3. Market Revenue and Forecast, by Age Group
13.3.11.4. Market Revenue and Forecast, by Provider Type
13.3.11.5. Market Revenue and Forecast, by End Use Purpose
13.4. MEA
13.4.1. Market Revenue and Forecast, by Treatment Type
13.4.2. Market Revenue and Forecast, by Gender
13.4.3. Market Revenue and Forecast, by Age Group
13.4.4. Market Revenue and Forecast, by Provider Type
13.4.5. Market Revenue and Forecast, by End Use Purpose
13.4.6. GCC
13.4.6.1. Market Revenue and Forecast, by Treatment Type
13.4.6.2. Market Revenue and Forecast, by Gender
13.4.6.3. Market Revenue and Forecast, by Age Group
13.4.6.4. Market Revenue and Forecast, by Provider Type
13.4.7. Market Revenue and Forecast, by End Use Purpose
13.4.8. North Africa
13.4.8.1. Market Revenue and Forecast, by Treatment Type
13.4.8.2. Market Revenue and Forecast, by Gender
13.4.8.3. Market Revenue and Forecast, by Age Group
13.4.8.4. Market Revenue and Forecast, by Provider Type
13.4.9. Market Revenue and Forecast, by End Use Purpose
13.4.10. South Africa
13.4.10.1. Market Revenue and Forecast, by Treatment Type
13.4.10.2. Market Revenue and Forecast, by Gender
13.4.10.3. Market Revenue and Forecast, by Age Group
13.4.10.4. Market Revenue and Forecast, by Provider Type
13.4.10.5. Market Revenue and Forecast, by End Use Purpose
13.4.11. Rest of MEA
13.4.11.1. Market Revenue and Forecast, by Treatment Type
13.4.11.2. Market Revenue and Forecast, by Gender
13.4.11.3. Market Revenue and Forecast, by Age Group
13.4.11.4. Market Revenue and Forecast, by Provider Type
13.4.11.5. Market Revenue and Forecast, by End Use Purpose
13.5. Latin America
13.5.1. Market Revenue and Forecast, by Treatment Type
13.5.2. Market Revenue and Forecast, by Gender
13.5.3. Market Revenue and Forecast, by Age Group
13.5.4. Market Revenue and Forecast, by Provider Type
13.5.5. Market Revenue and Forecast, by End Use Purpose
13.5.6. Brazil
13.5.6.1. Market Revenue and Forecast, by Treatment Type
13.5.6.2. Market Revenue and Forecast, by Gender
13.5.6.3. Market Revenue and Forecast, by Age Group
13.5.6.4. Market Revenue and Forecast, by Provider Type
13.5.7. Market Revenue and Forecast, by End Use Purpose
13.5.8. Rest of LATAM
13.5.8.1. Market Revenue and Forecast, by Treatment Type
13.5.8.2. Market Revenue and Forecast, by Gender
13.5.8.3. Market Revenue and Forecast, by Age Group
13.5.8.4. Market Revenue and Forecast, by Provider Type
13.5.8.5. Market Revenue and Forecast, by End Use Purpose
14.1. Ipsen
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. Medytox Inc.
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. Merz Pharma
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. Cutera Inc.
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. Syneron Candela
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. Sciton Inc.
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. Venus Concept
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. InMode Ltd.
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. Ulthera Inc
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
14.10. Sinclair Pharma
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
16.1. About Us
16.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Get a Sample
Report Description
Get a Sample
Report Description